Subscribe to RSS
Download PDF
DOI: 10.1055/a-2572-0833
Cumulative Serum Endothelin-1 and Endothelin-3 Level Predicts 1-year Adverse Cardiac Events after ST-Elevation Acute Myocardial Infarction
Funding This study and publication was supported by: (1) Dana Masyarakat FK-KMK Universitas Gadjah Mada, Yogyakarta, Indonesia (Number: 761/UN1/FKKMK/PPKE/PT/2023), and (2) Academic Excellence Improvement Program Universitas Gadjah Mada, under Grant (Number: 7725/UN1.P.II/Dit-Lit/PT.01.03/2023).
Abstract
Background
Endothelin-1 (ET-1) and endothelin-3 (ET-3) released in circulation during acute myocardial infarction (AMI) contribute to vasoconstriction, which elevates the severity of the myocardial infarction. This study aims to investigate the role of cumulative ET-1 and ET-3 levels on the major adverse cardiac events (MACE) 1 year after AMI hospitalization.
Materials and Methods
This retrospective cohort study included patients with ST-elevation acute myocardial infarction (STEMI). Baseline data were collected, including sociodemographic characteristics, clinical data, and serum ET-1 and ET-3 levels, measured with ELISA assay. Follow-up was performed 1 year after hospital discharge to identify MACE. A multivariate logistic regression was performed to describe predictors of 1-year MACE.
Results
A total of 81 subjects were enrolled and followed up. Subjects were divided into two groups based on their cumulative ET-1 and ET-3 levels, using a rounded cut-off point of 17.0 ng/mL, produced by the ROC curve for MACE. At 1 year MACE occurred in 24 (29.3%) subjects. A multivariate analysis demonstrated that a cumulative ET-1 and ET-3 level >17.0 ng/mL was independently associated with 1-year MACE (aOR = 5.34, 95% CI: 1.36–21.07, p = 0.017).
Conclusion
A higher cumulative serum ET-1 and ET-3 level at admission predicts MACE in 1 year of follow-up after STEMI.
Publication History
Article published online:
30 April 2025
© 2025. International College of Angiology. This article is published by Thieme.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Lee YH, Fang J, Schieb L, Park S, Casper M, Gillespie C. Prevalence and trends of coronary heart disease in the United States, 2011 to 2018. JAMA Cardiol 2022; 7 (04) 459-462
- 2 Heron M. Deaths: Leading Causes for 2019 [Internet]. 2021 . Accessed October 27, 2023 at: https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-09-508.pdf
- 3 Agency of Health Research and Development. Laporan Nasional Riskesdas 2018 (National Report of Basic Health Research 2018) [Internet]. 2019 . Accessed January 18, 2023 at: https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan%20Riskesdas%202018%20Nasional.pdf
- 4 Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Population Estimates 1950–2017 [Internet]. 2018 . Accessed January 18, 2023 at: https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf
- 5 MacDonald MR, Tay WT, Teng TK. et al; ASIAN-F investigators. Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF Registry. J Am Heart Assoc 2020; 9 (01) e012199 . Erratum in: J Am Heart Assoc. 2020 Mar 3;9(5):e014512
- 6 Stătescu C, Anghel L, Tudurachi BS, Leonte A, Benchea LC, Sascău RA. From classic to modern prognostic biomarkers in patients with acute myocardial infarction. Int J Mol Sci 2022; 23 (16) 9168
- 7 Katsioupa M, Kourampi I, Oikonomou E. et al. Novel biomarkers and their role in the diagnosis and prognosis of acute coronary syndrome. Life (Basel) 2023; 13 (10) 1992
- 8 Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Endothelin and the cardiovascular system: the long journey and where we are going. Biology (Basel) 2022; 11 (05) 759
- 9 Hartopo AB, Sukmasari I, Puspitawati I, Setianto BY. Serum endothelin-1 correlates with myocardial injury and independently predicts adverse cardiac events in non-ST-elevation acute myocardial infarction. Int J Vasc Med 2020; 2020: 9260812
- 10 Setianto BY, Hartopo AB, Sukmasari I, Puspitawati I. On-admission high endothelin-1 level independently predicts in-hospital adverse cardiac events following ST-elevation acute myocardial infarction. Int J Cardiol 2016; 220: 72-76
- 11 Zymliński R, Sierpiński R, Metra M. et al. Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. ESC Heart Fail 2020; 7 (06) 3536-3544
- 12 Hartopo AB, Puspitawati I, Mumpuni H. The ratio of circulating endothelin-1 to endothelin-3 associated with TIMI risk and dynamic TIMI risk score in ST elevation acute myocardial infarction. Can J Physiol Pharmacol 2020; 98 (09) 637-643
- 13 Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA 2022; 327 (07) 662-675
- 14 Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW. Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the Korean population. J Am Heart Assoc 2019; 8 (12) e010541
- 15 Liu X. Classification accuracy and cut point selection. Stat Med 2012; 31 (23) 2676-2686
- 16 Janjani P, Motevaseli S, Salehi N, Heidari Moghadam R, Siabani S, Nalini M. Predictors of 1-year major cardiovascular events after ST-elevation myocardial infarction in a specialized cardiovascular center in western Iran. J Tehran Heart Cent 2022; 17 (02) 62-70
- 17 Quesada O, Yildiz M, Henry TD. et al. Mortality in ST-segment elevation myocardial infarction with nonobstructive coronary arteries and mimickers. JAMA Netw Open 2023; 6 (11) e2343402
- 18 Mori F, King GL, Clermont AC, Bursell DK, Bursell SE. Endothelin-3 regulation of retinal hemodynamics in nondiabetic and diabetic rats. Invest Ophthalmol Vis Sci 2000; 41 (12) 3955-3962
- 19 Wellings RP, Corder R, Warner TD, Cristol JP, Thiemermann C, Vane JR. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br J Pharmacol 1994; 111 (02) 515-520
- 20 Pernow J, Böhm F, Johansson BL, Hedin U, Rydén L. Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol 2000; 36 (5, suppl 1): S418-S420
- 21 Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16 (08) 1081-1098
- 22 Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012; 84 (02) 147-162
- 23 Kolettis TM. Endothelin-1 during myocardial ischaemia: a double-edged sword?. Hypertens Res 2011; 34 (02) 170-172
- 24 Freixa X, Heras M, Ortiz JT. et al. Usefulness of endothelin-1 assessment in acute myocardial infarction. Rev Esp Cardiol 2011; 64 (02) 105-110